Educational Activities

Show Filters
Hide Filters
1-6 of 16 Activities
Title
Availability
Format
Credits
Course Opens
Buttons

Efficacy and Safety of Asparaginase-Containing Treatment Regimens in ALL/LBL and Beyond – An Interactive Review for Oncology Nurses and Nurse Practitioners

This CEC Oncology ONS Chapters Series is targeted to oncology nurses and advanced nurse practitioners serving as part of an interprofessional healthcare team providing care for pediatric and adult patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL).

This activity is no longer available for credit.
1.0
03/14/2023

Sandra Kurtin, PhD, ANP-C, AOCN

Sandra Kurtin, PhD, ANP-C, AOCN

Meeting Complex Challenges in Proteinuric Glomerular Disease: An Expert Review of Emerging Data and Novel Therapeutics for IgA Nephropathy

This activity will take learners on a deep dive into the pathophysiology of proteinuric glomerular disease, with an incisive focus on IgA nephropathy (IgAN). Expert faculty will review the totality of emerging evidence for novel therapeutics in IgAN, including an appraisal of consensus guidelines and regulatory updates. Finally, the session will conclude with a case-based segment wherein attendees will get to apply the principles they’ve learned to real-world clinical scenarios.

This activity is no longer available for credit.

1.00
04/06/2023

Jai Radhakrishnan, MD

Jai Radhakrishnan, MD

Richard Lafayette, MD

Richard Lafayette, MD

On-Demand
Webcast
1.5
12/22/2023

The Ever-Changing Options for the Treatment of CLL

The treatment landscape for CLL has changed dramatically in the past 10 years. With three approved BTK inhibitors, and several more on the horizon, choosing which agent to use in the first-line continues to present a challenge to hematologists/oncologists and care teams. As the choice of first-line agent has ramifications for future lines of therapy, hematologists/oncologists need to be able to map out the treatment journey while keeping in mind that therapy resistance or intolerance may arise and that AEs may diminish adherence to therapy.

In this Creative Educational Concepts Enduring Webcast, expert faculty will guide learners through the latest clinical data that informs best practices (including sequencing BTKis), the rationale and support for combination therapies, and the need to factor in the needs and preferences of patients.

1.5
12/22/2023

Matthew S. Davids, MD, MMSc

Matthew S. Davids, MD, MMSc

Kerry A. Rogers, MD

Kerry A. Rogers, MD

Beth  Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO

Beth  Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO

On-Demand
Webinar
1
03/05/2024

Cancer-Associated VTE: Balancing Risk and Reward with Modern Anticoagulation

In this 60-minute program, expert faculty will review CA-VTE risk factors and management strategies, discuss optimal anticoagulation therapy selection and guideline adherence, and explore approaches to working with multidisciplinary teams.  Clinicians can expect to gain valuable insight that will help them understand and overcome barriers to adequate anticoagulant therapy for patients with cancer.

1
03/05/2024

Marc Carrier, MD, MSc, FRCPC

Marc Carrier, MD, MSc, FRCPC

On-Demand
Webinar
1.5
05/07/2024

Guiding Light: Oncology Nurses’ Vital Role in Supporting Patients Through CLL Therapy

In this Creative Educational Concepts (CEC) webcast, expert faculty will discuss strategies for differentiating patient- and disease-specific variables that inform CLL treatment selection, developing plans for managing new AEs, and addressing patient-related treatment barriers to improve adherence to CLL therapy.

1.5
05/07/2024

Nikki Barkett, BSN, RN, OCN

Nikki Barkett, BSN, RN, OCN

Amy L. Goodrich, RN, BSN, MSN, CRNP-AC

Amy L. Goodrich, RN, BSN, MSN, CRNP-AC

Moderator

Matthew S. Davids, MD, MMSc

Matthew S. Davids, MD, MMSc

Transforming Metastatic Breast Cancer Management: Harnessing the Power of Antibody-Drug Conjugate Therapies

This 90-minute enduring activity is led by a panel of breast cancer experts who will guide participants through a discussion of criteria to select patients to receive ADCs, adverse event (AE) management, and strategies to foster equitable care of patients with metastatic breast cancer (mBC).

1.5
05/16/2024

Deltra James

Deltra James

Patient/Patient Advocate

Lee S. Schwartzberg, MD, FACP

Lee S. Schwartzberg, MD, FACP

Hope S. Rugo, MD, FASCO

Hope S. Rugo, MD, FASCO

Moderator

Srigowri Kota

Srigowri Kota